Literature DB >> 30020421

Repurposing an Old Drug for a New Epidemic: Ursodeoxycholic Acid to Prevent Recurrent Clostridioides difficile Infection.

Brandon J Webb1,2, Ali Brunner3, Julia Lewis4, Clyde D Ford3, Bert K Lopansri1,4.   

Abstract

Recurrent Clostridioides difficile infection (rCDI) may be mediated in part by secondary bile acids. Here we report salvage therapy with ursodeoxycholic acid (UDCA) to prevent rCDI in 16 high-risk patients. Patients on UDCA had a low observed recurrence rate (12.5%). Controlled trials are needed to confirm these observations.

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30020421     DOI： 10.1093/cid/ciy568

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  8 in total

Review 1.  Capturing the environment of the Clostridioides difficile infection cycle.

Authors:  Matthew K Schnizlein; Vincent B Young
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2022-04-25       Impact factor: 73.082

Review 2.  Impact of Primary and Secondary Bile Acids on Clostridioides difficile Infection.

Authors:  Agata Łukawska; Agata Mulak
Journal:  Pol J Microbiol       Date:  2022-03-14

3.  Clinical effects of ursodeoxycholic acid on patients with ulcerative colitis may improve via the regulation of IL-23-IL-17 axis and the changes of the proportion of intestinal microflora.

Authors:  Zhengjun Wang; Jinhua Chen; Zhiping Chen; Longke Xie; Wen Wang
Journal:  Saudi J Gastroenterol       Date:  2021 May-Jun       Impact factor: 2.485

Review 4.  Clostridioides difficile therapeutics: guidelines and beyond.

Authors:  Robert Orenstein; Roberto L Patron
Journal:  Ther Adv Infect Dis       Date:  2019-08-13

5.  Inhibitory Effect of Ursodeoxycholic Acid on Clostridium difficile Germination Is Insufficient to Prevent Colitis: A Study in Hamsters and Humans.

Authors:  Lola-Jade Palmieri; Dominique Rainteau; Harry Sokol; Laurent Beaugerie; Marie Dior; Benoit Coffin; Lydie Humbert; Thibaut Eguether; André Bado; Sandra Hoys; Claire Janoir; Henri Duboc
Journal:  Front Microbiol       Date:  2018-11-22       Impact factor: 5.640

6.  Decreased secondary faecal bile acids in children with ulcerative colitis and Clostridioides difficile infection.

Authors:  Sarah Rotondo-Trivette; Beibei Wang; Christopher Gayer; Riddhi Parsana; Yihui Luan; Fengzhu Sun; Sonia Michail
Journal:  Aliment Pharmacol Ther       Date:  2021-07-04       Impact factor: 9.524

7.  Ridinilazole, a narrow spectrum antibiotic for treatment of Clostridioides difficile infection, enhances preservation of microbiota-dependent bile acids.

Authors:  Xi Qian; Karin Yanagi; Anne V Kane; Nicholas Alden; Ming Lei; David R Snydman; Richard J Vickers; Kyongbum Lee; Cheleste M Thorpe
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2020-06-29       Impact factor: 4.871

Review 8.  The post-hematopoietic cell transplantation microbiome: relationships with transplant outcome and potential therapeutic targets.

Authors:  Yannouck F Van Lier; Marcel R M Van den Brink; Mette D Hazenberg; Kate A Markey
Journal:  Haematologica       Date:  2021-08-01       Impact factor: 9.941
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.